Cargando…

Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders

There is an increasing interest in the study of the relation between alterations in systemic lipid metabolism and neurodegenerative disorders, in particular in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). In ALS these alterations are well described and evident not only with...

Descripción completa

Detalles Bibliográficos
Autores principales: Godoy-Corchuelo, Juan Miguel, Fernández-Beltrán, Luis C., Ali, Zeinab, Gil-Moreno, María J., López-Carbonero, Juan I., Guerrero-Sola, Antonio, Larrad-Sainz, Angélica, Matias-Guiu, Jorge, Matias-Guiu, Jordi A., Cunningham, Thomas J., Corrochano, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138405/
https://www.ncbi.nlm.nih.gov/pubmed/35625841
http://dx.doi.org/10.3390/biomedicines10051105
_version_ 1784714617319063552
author Godoy-Corchuelo, Juan Miguel
Fernández-Beltrán, Luis C.
Ali, Zeinab
Gil-Moreno, María J.
López-Carbonero, Juan I.
Guerrero-Sola, Antonio
Larrad-Sainz, Angélica
Matias-Guiu, Jorge
Matias-Guiu, Jordi A.
Cunningham, Thomas J.
Corrochano, Silvia
author_facet Godoy-Corchuelo, Juan Miguel
Fernández-Beltrán, Luis C.
Ali, Zeinab
Gil-Moreno, María J.
López-Carbonero, Juan I.
Guerrero-Sola, Antonio
Larrad-Sainz, Angélica
Matias-Guiu, Jorge
Matias-Guiu, Jordi A.
Cunningham, Thomas J.
Corrochano, Silvia
author_sort Godoy-Corchuelo, Juan Miguel
collection PubMed
description There is an increasing interest in the study of the relation between alterations in systemic lipid metabolism and neurodegenerative disorders, in particular in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). In ALS these alterations are well described and evident not only with the progression of the disease but also years before diagnosis. Still, there are some discrepancies in findings relating to the causal nature of lipid metabolic alterations, partly due to the great clinical heterogeneity in ALS. ALS presentation is within a disorder spectrum with Frontotemporal Dementia (FTD), and many patients present mixed forms of ALS and FTD, thus increasing the variability. Lipid metabolic and other systemic metabolic alterations have not been well studied in FTD, or in ALS–FTD mixed forms, as has been in pure ALS. With the recent development in lipidomics and the integration with other -omics platforms, there is now emerging data that not only facilitates the identification of biomarkers but also enables understanding of the underlying pathological mechanisms. Here, we reviewed the recent literature to compile lipid metabolic alterations in ALS, FTD, and intermediate mixed forms, with a view to appraising key commonalities or differences within the spectrum.
format Online
Article
Text
id pubmed-9138405
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91384052022-05-28 Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders Godoy-Corchuelo, Juan Miguel Fernández-Beltrán, Luis C. Ali, Zeinab Gil-Moreno, María J. López-Carbonero, Juan I. Guerrero-Sola, Antonio Larrad-Sainz, Angélica Matias-Guiu, Jorge Matias-Guiu, Jordi A. Cunningham, Thomas J. Corrochano, Silvia Biomedicines Review There is an increasing interest in the study of the relation between alterations in systemic lipid metabolism and neurodegenerative disorders, in particular in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). In ALS these alterations are well described and evident not only with the progression of the disease but also years before diagnosis. Still, there are some discrepancies in findings relating to the causal nature of lipid metabolic alterations, partly due to the great clinical heterogeneity in ALS. ALS presentation is within a disorder spectrum with Frontotemporal Dementia (FTD), and many patients present mixed forms of ALS and FTD, thus increasing the variability. Lipid metabolic and other systemic metabolic alterations have not been well studied in FTD, or in ALS–FTD mixed forms, as has been in pure ALS. With the recent development in lipidomics and the integration with other -omics platforms, there is now emerging data that not only facilitates the identification of biomarkers but also enables understanding of the underlying pathological mechanisms. Here, we reviewed the recent literature to compile lipid metabolic alterations in ALS, FTD, and intermediate mixed forms, with a view to appraising key commonalities or differences within the spectrum. MDPI 2022-05-10 /pmc/articles/PMC9138405/ /pubmed/35625841 http://dx.doi.org/10.3390/biomedicines10051105 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Godoy-Corchuelo, Juan Miguel
Fernández-Beltrán, Luis C.
Ali, Zeinab
Gil-Moreno, María J.
López-Carbonero, Juan I.
Guerrero-Sola, Antonio
Larrad-Sainz, Angélica
Matias-Guiu, Jorge
Matias-Guiu, Jordi A.
Cunningham, Thomas J.
Corrochano, Silvia
Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders
title Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders
title_full Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders
title_fullStr Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders
title_full_unstemmed Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders
title_short Lipid Metabolic Alterations in the ALS–FTD Spectrum of Disorders
title_sort lipid metabolic alterations in the als–ftd spectrum of disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138405/
https://www.ncbi.nlm.nih.gov/pubmed/35625841
http://dx.doi.org/10.3390/biomedicines10051105
work_keys_str_mv AT godoycorchuelojuanmiguel lipidmetabolicalterationsinthealsftdspectrumofdisorders
AT fernandezbeltranluisc lipidmetabolicalterationsinthealsftdspectrumofdisorders
AT alizeinab lipidmetabolicalterationsinthealsftdspectrumofdisorders
AT gilmorenomariaj lipidmetabolicalterationsinthealsftdspectrumofdisorders
AT lopezcarbonerojuani lipidmetabolicalterationsinthealsftdspectrumofdisorders
AT guerrerosolaantonio lipidmetabolicalterationsinthealsftdspectrumofdisorders
AT larradsainzangelica lipidmetabolicalterationsinthealsftdspectrumofdisorders
AT matiasguiujorge lipidmetabolicalterationsinthealsftdspectrumofdisorders
AT matiasguiujordia lipidmetabolicalterationsinthealsftdspectrumofdisorders
AT cunninghamthomasj lipidmetabolicalterationsinthealsftdspectrumofdisorders
AT corrochanosilvia lipidmetabolicalterationsinthealsftdspectrumofdisorders